RESEARCH ARTICLE
Pharmacokinetics of a Mono-pyridinium-mono-aldoxime (K-347), a Potential Antidote in Organophosphate Poisoning
Huba Kalász1, *, Gellért Karvaly2, Ferenc Szimrók1, Dóra Szabó3, Márton Milánkovits3, András Keglevich1, Jennifer Adeghate4, Ferenc Darvas5, Kamil Kuca6, Kamil Musilek6, Kornélia Tekes7
Article Information
Identifiers and Pagination:
Year: 2020Volume: 14
First Page: 99
Last Page: 107
Publisher ID: TOMCJ-14-99
DOI: 10.2174/1874104502014010099
Article History:
Received Date: 6/5/2020Revision Received Date: 3/9/2020
Acceptance Date: 11/9/2020
Electronic publication date: 13/11/2020
Collection year: 2020
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background:
Our recent work has been treating the pharmacokinetics of pyridinium aldoximes of various structures including their time-dependent distribution in the body of male rats and also the extent of blood-brain-barrier penetration.
Objective:
Our overall aim was to find a proper antidote in organophosphate poisoning with fast elimination.
Methods:
White male Wistar rats were intramuscularly injected with the aqueous solution of 3 µmol of K-347. The animals were sacrificed at different time periods following treatment; various tissues and body fluids were taken and homogenised. The level of K-347 was determined using reversed-phase HPLC. Dose-dependence of tissue level was also determined by using various doses, 3 µmol through 100 µmol of K-347.
Results:
The serum level of K-347 showed a definitely fast decline. K347 did not have any effect on Gram-positive and Gram-negative bacteria that we tested.
Conclusion:
The kinetics of K-347 showed an extremely fast offset, even in comparison with several other pyridinium aldoximes in clinical practice and in developmental stages.